| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As an isotope-labeled internal standard, Progesterone-d9 does not have a defined biological target as a standalone compound. Its primary application is as an analytical standard for the quantification of the endogenous steroid hormone progesterone. Progesterone, the non-deuterated parent compound, is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy. It binds to and activates progesterone receptors, modulating the transcription of genes involved in reproductive function. Progesterone is implicated in the etiology of breast cancer.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a deuterated internal standard, Progesterone-d9 does not have intrinsic in vitro biological activity that is separately characterized from its non-deuterated parent compound. Progesterone, the non-labeled form, is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy. In vitro, it binds to and activates progesterone receptors, modulating the transcription of progesterone-responsive genes. Its activity is typically assessed in cell-based reporter assays using progesterone response element (PRE)-luciferase constructs. The deuterated form serves as an internal standard in these studies. |
| ln Vivo |
Progesterone-d9 is not used for in vivo pharmacological activity assessment as a standalone compound. Its primary application is as an internal standard for the quantification of progesterone in biological samples. Progesterone, the non-deuterated form, is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy. It is produced by the corpus luteum and induces maturation and secretory activity of the uterine endothelium while suppressing ovulation. Progesterone is used in hormone replacement therapy. The deuterated internal standard enables accurate measurement of progesterone levels.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Progesterone-d9 typically involve its use as an internal standard in competitive binding assays rather than as a test compound itself. The non-deuterated progesterone can be assessed for binding affinity to progesterone receptor using radioligand binding assays with [³H]-progesterone or other appropriate tracers. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. Binding affinity is expressed as IC₅₀ or Kd values. The deuterated compound serves as a quality control standard.
|
| Cell Assay |
In vitro cell-based assays using Progesterone-d9 typically employ the compound as an internal standard for LC-MS/MS quantification in cell culture media or cell lysates rather than as a test compound. For studying progesterone's biological activity, cell lines expressing progesterone receptor are used to assess receptor activation through reporter gene assays with PRE-luciferase constructs. Gene expression analysis by qPCR can also be employed. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media are used.
|
| Animal Protocol |
In vivo animal studies utilizing Progesterone-d9 typically involve administration of the deuterated compound as a tracer or internal standard for pharmacokinetic or pharmacodynamic studies. The compound is used to quantify endogenous progesterone levels in plasma, urine, and tissue samples from animal models of reproductive function or hormone replacement therapy. Typical study designs involve sample collection at various time points, followed by LC-MS/MS analysis using Progesterone-d9 as the internal standard. All procedures comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Progesterone-d9 is used as an internal standard for the quantification of progesterone by GC- or LC-mass spectrometry. It has a molecular weight of 323.52 g/mol and a molecular formula of C₂₁H₂₁D₉O₂. As an isotope-labeled compound, its chromatographic and mass spectrometric behavior is nearly identical to that of non-deuterated progesterone, allowing for precise correction of analytical variability. The compound is typically stored at 2-8°C refrigerated. Its pharmacokinetic properties as a tracer mirror those of endogenous progesterone.
|
| Toxicity/Toxicokinetics |
Progesterone-d9 is intended for research and analytical use only and is not approved for human therapeutic applications. As a stable isotope-labeled internal standard, it is used in trace quantities in analytical methods and does not present significant toxicological concerns at these levels. The non-deuterated parent compound, progesterone, is an endogenous steroid hormone with well-characterized physiological effects. Standard laboratory safety precautions should be observed when handling Progesterone-d9.
|
| References | |
| Additional Infomation |
Progesterone-d9 (Pregn-4-ene-3,20-dione-d9) (CAS#: 15775-74-3) has a molecular formula of C₂₁H₂₁D₉O₂ and a molecular weight of 323.52 g/mol. It is the deuterium-labeled form of Progesterone. Progesterone is a steroid hormone that regulates the menstrual cycle and is crucial for pregnancy. It is produced by the corpus luteum, induces uterine endometrial maturation, and suppresses ovulation. Progesterone-d9 is intended for use as an internal standard for GC- or LC-MS quantification. This compound is not a drug and is strictly a research reagent.
|
| Molecular Formula |
C21H21D9O2
|
|---|---|
| Molecular Weight |
323.52
|
| Exact Mass |
323.281
|
| CAS # |
15775-74-3
|
| Related CAS # |
Progesterone;57-83-0
|
| PubChem CID |
71309321
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
447.2±45.0 °C at 760 mmHg
|
| Melting Point |
128-132 °C
|
| Flash Point |
166.7±25.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
4.04
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
589
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
[2H]C1=C2[C@](CC(C1=O)([2H])[2H])([C@H]3CC[C@]4([C@H]([C@@H]3CC2([2H])[2H])CC[C@]4([2H])C(=O)C([2H])([2H])[2H])C)C
|
| InChi Key |
RJKFOVLPORLFTN-PQIPVKAESA-N
|
| InChi Code |
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1/i1D3,4D2,8D2,12D,17D
|
| Chemical Name |
(8S,9S,10R,13S,14S,17S)-2,2,4,6,6,17-hexadeuterio-10,13-dimethyl-17-(2,2,2-trideuterioacetyl)-7,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0910 mL | 15.4550 mL | 30.9100 mL | |
| 5 mM | 0.6182 mL | 3.0910 mL | 6.1820 mL | |
| 10 mM | 0.3091 mL | 1.5455 mL | 3.0910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
